{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T05:09:01Z","timestamp":1778476141494,"version":"3.51.4"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"\n Introduction<\/jats:title>\n Skin cancers are the most common malignancy worldwide, and identifying populations with altered risk is essential for informing prevention and surveillance strategies. Emerging evidence suggests that alopecia areata (AA) may be associated with reduced skin cancer risk, potentially reflecting enhanced cytotoxic immune activity.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n We conducted a systematic review and meta-analysis to evaluate the incidence of skin cancers in patients with AA. PubMed, Embase, Scopus, and ClinicalTrials.gov were searched through July 2025. Of 1, 039 records identified, eight studies met inclusion criteria, with six included in the quantitative synthesis.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n AA was associated with a statistically significant reduction in melanoma incidence (OR 0.58; 95% CI, 0.36-0.94; p = 0.028). Overall skin cancer risk was reduced but not statistically significant (OR 0.58, 95% CI, 0.27-1.22). Pooled estimates for basal cell carcinoma (OR 0.43; 95% CI, 0.11-1.75) and squamous cell carcinoma (OR 0.66; 95% CI, 0.28-1.57) suggested directionally reduced associations, but did not reach statistical significance. Between-study heterogeneity was high (I\n 2<\/jats:sup>\n &gt;80% for BCC and SCC), however sensitivity analyses, including leave-one-out tests, confirmed the stability of the protective trend.\n <\/jats:p>\n <\/jats:sec>\n \n Discussion<\/jats:title>\n These findings suggest that AA is not associated with increased skin cancer risk and demonstrates an inverse association with melanoma incidence, although substantial heterogeneity and sensitivity analyses warrant cautious interpretation. These results provide important baseline context for patient counseling and for interpreting longterm safety data as systemic therapies, including JAK inhibitors, are increasingly used.<\/jats:p>\n <\/jats:sec>\n \n Systematic Review Registration<\/jats:title>\n \n https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>\n , identifier CRD420251123793.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fonc.2026.1787992","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T04:26:18Z","timestamp":1778473578000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Skin cancer risk in alopecia areata: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Simonetta I.","family":"Gaumond","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Miller School of Medicine, University of Miami","place":["Miami, FL, United States"]},{"name":"Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami","place":["Miami, FL, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alireza","family":"Abdshah","sequence":"additional","affiliation":[{"name":"Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami","place":["Miami, FL, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabella","family":"Kamholtz","sequence":"additional","affiliation":[{"name":"Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami","place":["Miami, FL, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peyton V.","family":"Warp","sequence":"additional","affiliation":[{"name":"Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami","place":["Miami, FL, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keyvan","family":"Nouri","sequence":"additional","affiliation":[{"name":"Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami","place":["Miami, FL, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Tosti","sequence":"additional","affiliation":[{"name":"Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami","place":["Miami, FL, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joaquin J.","family":"Jimenez","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Miller School of Medicine, University of Miami","place":["Miami, FL, United States"]},{"name":"Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami","place":["Miami, FL, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2025.1276","article-title":"Burden of skin cancer in older adults from 1990 to 2021 and modelled projection to 2050","volume":"161","author":"Wang","year":"2025","journal-title":"JAMA Dermatol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.cpt.2024.08.002","article-title":"Overview of skin cancer types and prevalence rates across continents","volume":"3","author":"Roky","year":"2025","journal-title":"Cancer Pathog Ther"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/pon.6034","article-title":"Financial worry in people with cancer: Relationship to employment and outcomes","volume":"31","author":"Jones","year":"2022","journal-title":"Psychooncology"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.03.109","article-title":"United States burden of melanoma and non-melanoma skin cancer from 1990 to 2019","volume":"85","author":"Aggarwal","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1159\/000545345","article-title":"Scarring alopecia and risk of skin cancer: A literature review","volume":"11","author":"Lee","year":"2025","journal-title":"Skin Appendage Disord"},{"key":"B6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jdermsci.2016.10.004","article-title":"Alopecia areata: What\u2019s new in epidemiology, pathogenesis, diagnosis, and therapeutic options","volume":"86","author":"Dainichi","year":"2017","journal-title":"J Dermatol Sci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14155","article-title":"Hair follicle immune privilege and its collapse in alopecia areata","volume":"29","author":"Bertolini","year":"2020","journal-title":"Exp Dermatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.5680","article-title":"Immune-mediated diseases associated with cancer risks","volume":"8","author":"He","year":"2022","journal-title":"JAMA Oncol"},{"key":"B9","unstructured":"Autoimmune diseases and cancer\n \n \n \n Ehrenfeld\n M\n \n \n Bogota, Colombia\n El Rosario University Press\n Autoimmunity: from bench to bedside\n \n 2013"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-025-01520-0","article-title":"Cancer risk in vitiligo: No evidence of increased prevalence-a systematic review and meta-analysis","volume":"15","author":"Mohammed","year":"2025","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"691","DOI":"10.2147\/CCID.S309215","article-title":"A comprehensive literature review of JAK inhibitors in treatment of alopecia areata","volume":"14","author":"Dillon","year":"2021","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-025-01517-9","article-title":"Evaluating current and emergent JAK inhibitors for alopecia areata: A narrative review","author":"Sanchez","year":"2025","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-01044-5","article-title":"Treatments for moderate-to-severe alopecia areata: A systematic narrative review","volume":"13","author":"Egeberg","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.envint.2024.108602","article-title":"A tool to assess risk of bias in non-randomized follow-up studies of exposure effects (ROBINS-E)","volume":"186","author":"Higgins","year":"2024","journal-title":"Environ Int"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J Stat Softw"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/jidsymp.2015.44","article-title":"Prevalence of comorbid conditions and sun-induced skin cancers in patients with alopecia areata","volume":"17","author":"Miller","year":"2015","journal-title":"J Investig Dermatol Symp Proc"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2016.02.009","article-title":"Reduced incidence of skin cancer in patients with alopecia areata: A retrospective cohort study","volume":"41","author":"Mostaghimi","year":"2016","journal-title":"Cancer Epidemiol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15002","article-title":"Risk of sun-induced skin cancers in patients with alopecia areata, alopecia totalis and alopecia universalis","volume":"32","author":"Conic","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-00937-9","article-title":"Incidence rates of infections, Malignancies, thromboembolism, and cardiovascular events in an alopecia areata cohort from a US claims database","volume":"13","author":"George","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1093\/bjd\/ljaf074","article-title":"Incidence, stage and outcome of Malignant melanoma, keratinocyte and other cancers in individuals with vitiligo or alopecia: Intraindividual or familial risks","volume":"193","author":"Delcoigne","year":"2025","journal-title":"Br J Dermatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v105.42646","article-title":"Rates of infections, Malignancies, cardiovascular outcomes, and death in individuals with hospital-treated alopecia areata: A registry-based cohort study in Denmark","volume":"105","author":"S\u00f8rensen","year":"2025","journal-title":"Acta Derm Venereol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1448","article-title":"Cancer risk in patients with alopecia areata: A nationwide population-based matched cohort study","volume":"7","author":"Chen","year":"2018","journal-title":"Cancer Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"9748","DOI":"10.1038\/s41598-018-28142-1","article-title":"Cancer risk by the subtype of alopecia","volume":"8","author":"Lee","year":"2018","journal-title":"Sci Rep"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00847","article-title":"Interferon-gamma at the crossroads of tumor immune surveillance or evasion","volume":"9","author":"Castro","year":"2018","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-22-0326","article-title":"Coexisting alterations of MHC class I antigen presentation and IFN\u03b3 signaling mediate acquired resistance of melanoma to post-PD-1 immunotherapy","volume":"10","author":"Nielsen","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.4161\/2162402X.2014.974959","article-title":"IFN\u03b3 producing CD8+ T cells modified to resist major immune checkpoints induce regression of MHC class I-deficient melanomas","volume":"4","author":"Buferne","year":"2015","journal-title":"Oncoimmunology"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.4110\/in.2024.24.e11","article-title":"IL-15 in T-cell responses and immunopathogenesis","volume":"24","author":"Lee","year":"2024","journal-title":"Immune Netw"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1302291","article-title":"Qualitatively different T cell phenotypic responses to IL-2 versus IL-15 are unified by identical dependences on receptor signal strength and duration","volume":"192","author":"Arneja","year":"2014","journal-title":"J Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/nri1901","article-title":"The biology of interleukin-2 and interleukin-15: Implications for cancer therapy and vaccine design","volume":"6","author":"Waldmann","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1184703","article-title":"Research progress of interleukin-15 in cancer immunotherapy","volume":"14","author":"Cai","year":"2023","journal-title":"Front Pharmacol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000599","article-title":"Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-\u03b3, CXCL9 and CXCL10","volume":"8","author":"Bergamaschi","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2300343120","article-title":"XCR1 expression distinguishes human conventional dendritic cell type 1 with full effector functions from their immediate precursors","volume":"120","author":"Heger","year":"2023","journal-title":"Proc Natl Acad Sci"},{"key":"B35","unstructured":"Harnessing the cDC1-NK cross-talk in the tumor microenvironment to battle cancer\n \n \n \n B\u00f6dder\n J\n \n \n Zahan\n T\n \n \n van Slooten\n R\n \n \n Schreibelt\n G\n \n \n de Vries\n IJM\n \n \n Fl\u00f3rez-Grau\n G\n \n \n \n 2021"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2017.08.010","article-title":"The potential and promise of IL-15 in immuno-oncogenic therapies","volume":"190","author":"Robinson","year":"2017","journal-title":"Immunol Lett"},{"key":"B37","unstructured":"Cancer immune evasion through loss of MHC class I antigen presentation\n \n \n \n DhatChinamoorthy\n K\n \n \n Colbert\n JD\n \n \n Rock\n KL\n \n \n \n 2021"},{"key":"B38","unstructured":"Adaptations of natural killer cells to self-MHC class I\n \n \n \n Bessoles\n S\n \n \n Grandcl\u00e9ment\n C\n \n \n Alari-Pahissa\n E\n \n \n Gehrig\n J\n \n \n Jeevan-Raj\n B\n \n \n Held\n W\n \n \n \n 2014"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000610","article-title":"Natural killer cell recognition and control of epithelial cancers","volume":"28","author":"de Souza Fernandez Pereira","year":"2022","journal-title":"Cancer J"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1038\/s41467-020-15726-7","article-title":"Transcriptional downregulation of MHC class I and melanoma de-differentiation in resistance to PD-1 inhibition","volume":"11","author":"Lee","year":"2020","journal-title":"Nat Commun"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12071760","article-title":"MHC class I downregulation in cancer: Underlying mechanisms and potential targets for cancer immunotherapy","volume":"12","author":"Cornel","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B42","unstructured":"Mechanisms of MHC-I downregulation and role in immunotherapy response\n \n \n \n Taylor\n BC\n \n \n Balko\n JM\n \n \n \n 2022"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaf092","article-title":"Cancer risk of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs among older Americans with rheumatoid arthritis","volume":"64","author":"Ahmed","year":"2025","journal-title":"Rheumatol (Oxford)"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1787992\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T04:26:20Z","timestamp":1778473580000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1787992\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":44,"alternative-id":["10.3389\/fonc.2026.1787992"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1787992","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"article-number":"1787992"}}